Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -28,240
▼ 138% vs 2024
Profit
Caution€ -127,809
▼ 58% vs 2024
Debts
Low€ 181,871
▼ 9% vs 2024
Railroad Therapeutics from Charleroi, company number BE0792976285, closed financial year 2025 with a result of € -127,809 after tax. For that financial year Railroad Therapeutics recorded a gross margin of € -28,240 and equity of € 437,751. Compared with financial year 2024, the result moved from € -80,862 to € -127,809. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.
What happened at Railroad Therapeutics?
What happened at Railroad Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 127,809. Source: NBB ↗
- Sofie Pattyn became a director. NBB
- Yvan Sergeant became a director. NBB
- 6K venture capital became a director. NBB
- Jakub Swiercz became a director. NBB
- Sciensation became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 9,918 profit in 2023 to € 127,809 loss in 2025.
Best year ever: 2023, with € 9,918 profit.
A new publication or filing at Railroad Therapeutics? We notify you, reason included.
Follow Railroad TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Railroad Therapeutics are 6K venture capital, Sofie Pattyn, Jakub Swiercz, Yvan Sergeant and Sciensation. The same people are also behind Charleroi Entreprendre, Brussels South Charleroi BioPark Dev, HOME EOS, FONDS D'INVESTISSEMENT POUR LA DIVERSIFICATION INDUSTRIELLE DE LA REGION DE CHARLEROI and Biometh Quality Product.
Directors
According to the 2025 annual accounts
Director · represented by Cédric Szpirer
Also active at: Charleroi Entreprendre, Brussels South Charleroi BioPark Dev, HOME EOS +12 more
since 2025
since 2025
Jakub Swiercz
Director
since 2025
Yvan Sergeant
Director
since 2025
Director · represented by Frédéric Sallmann
since 2025
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Rue Auguste Piccard 48
6041 Charleroi
Active since 27 October 2022
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
Brussels South Charleroi BioPark Dev same network
€ 80,186 gross margin · 2025
ImmunXperts same network
€ 393,338 gross margin · 2024
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
+26 more
Details
- Company number
- 0792.976.285
- VAT number
- BE 0792.976.285
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- Railroad Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 October 2022
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Speur- en ontwikkelingswerk op het gebied van de maatschappij- en geesteswetenschappen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied